You just read:

Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

Apr 04, 2019, 08:30 ET